Welcome to our dedicated page for Enova International SEC filings (Ticker: ENVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Enova International's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Enova International's regulatory disclosures and financial reporting.
Form 144 notice for Enova International, Inc. (ENVA) reports a proposed sale of 2,965 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $363,612.78. The shares represent part of the issuer's outstanding common stock of 25,012,613 shares and are scheduled for sale on 08/28/2025 on the NYSE. The shares were acquired as restricted stock from the issuer on 02/23/2019 and payment was recorded as Not Applicable. The filer states there were no securities sold in the past three months for the account to be sold. Certain filer identification fields (CIK/CCC and submission contact details) are not provided in the document.
Enova International insider transaction by CEO David Fisher: The filing shows Mr. Fisher, who is both Chief Executive Officer and a director, completed offsetting transactions on 08/26/2025. He acquired 5,000 shares via exercise at an exercise price of $23.96, bringing his beneficial ownership to 353,223 shares. On the same date he sold 5,000 shares under a Rule 10b5-1 plan at a weighted average price of $117.8003, reducing post-transaction shares to 348,223. The sale executed in multiple trades at prices between $114.27 and $118.57. The filing also discloses the structure and vesting of related options and limited SARs and notes the option vesting schedule in 2020–2022.
Enova International insider sale notice under Rule 144: The filing reports a proposed sale of 15,000 shares of Enova common stock through Merrill Lynch on or about 08/28/2025, with an aggregate market value of $1,815,000 (implying $121.00 per share). The shares were acquired on 02/12/2019 via stock options granted by Enova International. The filer, identified in related sales as David Fisher at a Chicago address, sold 2,000 shares on 06/20/2025, 5,000 on 07/14/2025, and 5,000 on 08/28/2025 for total gross proceeds of $1,361,515.97. The company has 25,012,613 shares outstanding per the form. The signer certifies no undisclosed material adverse information and references Rule 10b5-1 compliance language.
Enova International, Inc. Form 144 notice shows a proposed sale of 5,000 common shares through Merrill Lynch (Chicago) with an aggregate market value of $575,000, to be sold approximately on 08/26/2025 on the NYSE. The filer indicates these 5,000 shares were originally acquired on 02/12/2019 from Enova International via stock options. The filing also discloses two recent sales by the same person within the past three months: 2,000 shares sold on 06/20/2025 for $196,762.87 and 5,000 shares sold on 07/14/2025 for $575,951.66. The form includes a representation that the seller does not possess undisclosed material adverse information and references Rule 10b5-1 planning language.
Enova International (ENVA) reported a proposed insider sale of 17,000 common shares, with an aggregate market value of $1,849,549. The shares were acquired and paid for by the seller on 08/12/2025 through a stock option exercise, with payment made in cash. The intended sale is to be executed the same day through Morgan Stanley Smith Barney LLC on the NYSE. The filing lists 25,012,613 shares outstanding for the issuer and shows no sales in the past three months by the selling person. The notice includes the seller's representation that they do not possess undisclosed material information. Several filer identification fields (CIK and filer name) are left blank in this document.
Form 4 filed for Enova International (ENVA) reports a new equity award to CEO & Director David Fisher. On 08/06/2025 Fisher received a non-qualified stock option covering 22,401 common shares at an exercise price of $103.92. The option carries a tandem limited stock appreciation right that can be exercised only within 30 days following a defined Change-in-Control event.
Vesting: the option vests in three equal one-third tranches on Aug 6, 2026 / 2027 / 2028, contingent on continued employment. It expires on 08/06/2032. Following the grant, Fisher now beneficially owns 22,401 derivative securities; no purchases or sales of common shares were disclosed.
The transaction appears to be routine executive compensation rather than an opportunistic trade, modestly strengthening alignment between management and shareholders without creating immediate dilution or signaling directional sentiment.